• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

内镜反应评估对预测食管鳞癌新辅助化疗后残余肿瘤分布的临床意义。

Clinical Significance of Endoscopic Response Evaluation to Predict the Distribution of Residual Tumor after Neoadjuvant Chemotherapy for Esophageal Squamous Cell Carcinoma.

机构信息

Department of Surgery, Keio University School of Medicine, Tokyo, Japan.

Biostatistics Unit, Clinical and Translational Research Center, Keio University Hospital, Tokyo, Japan.

出版信息

Ann Surg Oncol. 2022 Apr;29(4):2673-2680. doi: 10.1245/s10434-021-11009-7. Epub 2021 Nov 23.

DOI:10.1245/s10434-021-11009-7
PMID:34812985
Abstract

PURPOSE

To appropriately adopt the organ preservation approach, including subsequent chemoradiotherapy (CRT) in patients who respond to neoadjuvant chemotherapy (NAC), the distribution of residual disease, including pathological lymph nodes (LNs) and recurrence site, needs to be recognized preoperatively. This study was designed to evaluate whether endoscopic response evaluation can predict residual tumor distribution.

METHODS

Patients with esophageal squamous cell carcinoma who underwent transthoracic esophagectomy (TTE) were retrospectively reviewed. Endoscopic responder (ER) to NAC was defined according to primary tumor endoscopic findings. Recurrence-free survival (RFS), overall survival (OS), and residual tumor patterns were compared between groups.

RESULTS

Of 193 patients, 40 (20%) were classified as ER. ERs showed significantly better RFS and OS. The pN location was found within the primary tumor and cN field in 88% of ERs, which was significantly higher than non-ERs at 63% (p = 0.004). Furthermore, the postoperative recurrence incidence in the distant organ was significantly lower in the ERs than the non-ERs (8%, 32%, respectively, p = 0.002). Residual disease, including postoperative initial recurrence, existed within the same field as the primary tumor and cN in 88% of ERs, significantly higher than 42% in the non-ERs (p < 0.001).

CONCLUSIONS

Endoscopic response evaluation can preoperatively predict distribution of residual tumors after NAC, which could help radiation field selection in subsequent definitive CRT when patients prefer to omit TTE. Along with improvements in NAC response rate, this could facilitate organ preservation in patients who respond to NAC.

摘要

目的

对于新辅助化疗(NAC)后有反应的患者,包括随后的放化疗(CRT),需要在术前识别器官保存方法,包括残留疾病,包括病理淋巴结(LN)和复发部位。本研究旨在评估内镜反应评估是否可以预测残留肿瘤的分布。

方法

回顾性分析了接受经胸食管切除术(TTE)的食管鳞癌患者。根据原发肿瘤内镜检查结果,将 NAC 内镜反应者(ER)定义为内镜反应者。比较两组之间的无复发生存率(RFS)、总生存率(OS)和残留肿瘤模式。

结果

在 193 例患者中,有 40 例(20%)被归类为 ER。ER 患者的 RFS 和 OS 明显更好。88%的 ER 患者的 pN 位置位于原发肿瘤内和 cN 野内,明显高于非 ER 患者的 63%(p=0.004)。此外,ER 患者的远处器官术后复发率明显低于非 ER 患者(8%、32%,分别为 p=0.002)。88%的 ER 患者的残留疾病,包括术后初始复发,存在于原发肿瘤和 cN 相同的部位,明显高于非 ER 患者的 42%(p<0.001)。

结论

内镜反应评估可在 NAC 后术前预测残留肿瘤的分布,当患者倾向于省略 TTE 时,有助于随后确定 CRT 时的放射野选择。随着 NAC 反应率的提高,这可以促进对 NAC 有反应的患者的器官保存。

相似文献

1
Clinical Significance of Endoscopic Response Evaluation to Predict the Distribution of Residual Tumor after Neoadjuvant Chemotherapy for Esophageal Squamous Cell Carcinoma.内镜反应评估对预测食管鳞癌新辅助化疗后残余肿瘤分布的临床意义。
Ann Surg Oncol. 2022 Apr;29(4):2673-2680. doi: 10.1245/s10434-021-11009-7. Epub 2021 Nov 23.
2
Prognostic significance of pathological tumor response and residual nodal metastasis in patients with esophageal squamous cell carcinoma after neoadjuvant chemotherapy followed by surgery.新辅助化疗后手术治疗的食管鳞癌患者病理肿瘤反应和残留淋巴结转移的预后意义。
Esophagus. 2019 Oct;16(4):395-401. doi: 10.1007/s10388-019-00679-8. Epub 2019 Jun 12.
3
Clinical significance of evaluating endoscopic response to neoadjuvant chemotherapy in esophageal squamous cell carcinoma.评估食管鳞癌新辅助化疗内镜反应的临床意义。
Dig Endosc. 2020 Jan;32(1):39-48. doi: 10.1111/den.13449. Epub 2019 Jul 17.
4
Prognostic impact of endoscopic response evaluation after neoadjuvant chemotherapy for esophageal squamous cell carcinoma: a nationwide validation study.新辅助化疗后内镜反应评估对食管鳞癌预后的影响:一项全国性验证研究。
Esophagus. 2023 Jul;20(3):455-464. doi: 10.1007/s10388-023-00998-x. Epub 2023 Mar 24.
5
Clinical tools do not predict pathological complete response in patients with esophageal squamous cell cancer treated with definitive chemoradiotherapy.临床工具无法预测接受根治性放化疗的食管鳞癌患者的病理完全缓解。
Dis Esophagus. 2014 May-Jun;27(4):355-9. doi: 10.1111/dote.12126. Epub 2013 Aug 29.
6
Comparison of neoadjuvant chemotherapy versus upfront surgery with or without chemotherapy for patients with clinical stage III esophageal squamous cell carcinoma.临床III期食管鳞状细胞癌患者新辅助化疗与先行手术加或不加化疗的比较。
Dis Esophagus. 2017 Feb 1;30(2):1-8. doi: 10.1111/dote.12473.
7
Oncologic Outcomes According to Remnant Lymph Node Metastases in Pathologic T0 (ypT0) Esophageal Squamous Cell Carcinoma Following Prospective Neoadjuvant Therapy and Surgery.前瞻性新辅助治疗及手术后,病理T0(ypT0)食管鳞状细胞癌中残留淋巴结转移的肿瘤学结局
Ann Surg Oncol. 2015;22(6):1851-7. doi: 10.1245/s10434-014-4195-3. Epub 2014 Oct 25.
8
Distribution of Residual Disease and Recurrence Patterns in Pathological Responders After Neoadjuvant Chemotherapy for Esophageal Squamous Cell Carcinoma.新辅助化疗后病理缓解的食管鳞癌患者的残留疾病分布和复发模式。
Ann Surg. 2022 Aug 1;276(2):298-304. doi: 10.1097/SLA.0000000000004436. Epub 2020 Oct 16.
9
Comparison of long-term outcomes between esophagectomy and chemoradiotherapy after endoscopic resection of submucosal esophageal squamous cell carcinoma.内镜下切除黏膜下食管鳞癌后行食管切除术与放化疗的长期疗效比较。
Dis Esophagus. 2019 Dec 31;32(12). doi: 10.1093/dote/doz023.
10
Residual Cancer Volume Predicts Clinical Outcome in Patients With Esophageal Squamous Cell Carcinoma After Neoadjuvant Chemotherapy.新辅助化疗后残余癌体积可预测食管鳞状细胞癌患者的临床结局
Int J Surg Pathol. 2019 Oct;27(7):713-721. doi: 10.1177/1066896919855760. Epub 2019 Jun 17.

引用本文的文献

1
Detection of pathologic complete response using deep neural network-based endoscopic evaluation in patients with esophageal cancer receiving neoadjuvant chemotherapy: a nationwide multicenter retrospective study from 46 Japanese esophageal centers.使用基于深度神经网络的内镜评估检测接受新辅助化疗的食管癌患者的病理完全缓解:一项来自日本46个食管癌中心的全国多中心回顾性研究。
Esophagus. 2025 Apr 28. doi: 10.1007/s10388-025-01130-x.
2
Liquid Biopsy and Multidisciplinary Treatment for Esophageal Cancer.食管癌的液体活检与多学科治疗
Cancers (Basel). 2025 Jan 9;17(2):196. doi: 10.3390/cancers17020196.
3
Enhancing Prediction for Tumor Pathologic Response to Neoadjuvant Immunochemotherapy in Locally Advanced Esophageal Cancer by Dynamic Parameters from Clinical Assessments.
通过临床评估的动态参数增强局部晚期食管癌新辅助免疫化疗肿瘤病理反应的预测
Cancers (Basel). 2023 Sep 1;15(17):4377. doi: 10.3390/cancers15174377.
4
Endoscopic Evaluation of Pathological Complete Response Using Deep Neural Network in Esophageal Cancer Patients Who Received Neoadjuvant Chemotherapy-Multicenter Retrospective Study from Four Japanese Esophageal Centers.使用深度神经网络对接受新辅助化疗的食管癌患者进行病理完全缓解的内镜评估——来自四个日本食管癌中心的多中心回顾性研究
Ann Surg Oncol. 2023 Nov;30(12):7472-7480. doi: 10.1245/s10434-023-13862-0. Epub 2023 Aug 5.
5
Prognostic impact of endoscopic response evaluation after neoadjuvant chemotherapy for esophageal squamous cell carcinoma: a nationwide validation study.新辅助化疗后内镜反应评估对食管鳞癌预后的影响:一项全国性验证研究。
Esophagus. 2023 Jul;20(3):455-464. doi: 10.1007/s10388-023-00998-x. Epub 2023 Mar 24.
6
Evaluation of Endoscopic Response Using Deep Neural Network in Esophageal Cancer Patients Who Received Neoadjuvant Chemotherapy.使用深度神经网络评估接受新辅助化疗的食管癌患者的内镜反应。
Ann Surg Oncol. 2023 Jun;30(6):3733-3742. doi: 10.1245/s10434-023-13140-z. Epub 2023 Mar 2.
7
ASO Author Reflections: Does AI Guided Endoscopic Response Evaluation After Neoadjuvant Chemotherapy Encourage Individualized Treatment Strategy in Esophageal Cancer Patients?ASO作者反思:新辅助化疗后人工智能引导的内镜反应评估是否鼓励食管癌患者采取个体化治疗策略?
Ann Surg Oncol. 2023 Jun;30(6):3743-3744. doi: 10.1245/s10434-023-13198-9. Epub 2023 Mar 2.
8
ASO Author Reflections: Value of Robotic Surgery in the Era of Opioid Crisis.《血管紧张素原作者反思:阿片类药物危机时代机器人手术的价值》
Ann Surg Oncol. 2022 Sep;29(9):5871-5872. doi: 10.1245/s10434-022-11889-3. Epub 2022 May 10.
9
Transmembrane 4 L Six Family Member 1 Suppresses Hormone Receptor--Positive, HER2-Negative Breast Cancer Cell Proliferation.跨膜4L六家族成员1抑制激素受体阳性、HER2阴性乳腺癌细胞增殖。
Front Pharmacol. 2022 Jan 27;13:770993. doi: 10.3389/fphar.2022.770993. eCollection 2022.
10
ASO Author Refections: Evaluation of Endoscopic Response After Neoadjuvant Chemotherapy Guides Distribution of Residual Diseases for Esophageal Squamous Cell Carcinoma.ASO作者反思:新辅助化疗后内镜反应评估指导食管鳞状细胞癌残余病灶的分布
Ann Surg Oncol. 2022 Apr;29(4):2681-2682. doi: 10.1245/s10434-021-11020-y. Epub 2021 Nov 11.